EVALUATION OF PROGESTERONE RECEPTOR EXPRESSION IN INVASIVE BREAST CARCINOMA
Main Article Content
Abstract
Background: Breast cancer remains one of the most prevalent malignancies among women in Vietnam. Approximately 70% of breast cancers are hormone receptor–positive (ER and/or PR). Hormone receptor status plays a critical role in determining prognosis and guiding endocrine therapy, which substantially reduces recurrence and improves survival. Objectives: To assess the expression of the progesterone receptor (PR) in invasive breast carcinoma and analyze its association with selected histopathological features. In addition, to compare PR expression between core needle biopsy samples and surgical specimens. Methods: This cross-sectional study included 103 paraffin-embedded breast tissue samples obtained from female patients diagnosed histopathologically with invasive breast carcinoma who underwent surgery at Hanoi Medical University Hospital from January 2024 to June 2025. PR expression was evaluated according to the Allred scoring system. Data were analyzed using SPSS version 26.0. Results: PR positivity was detected in 66.0% of breast carcinoma cases, with the low-positive group (1–10%) accounting for 7.8%. Positive PR expression was significantly more common in patients aged ≤45 years and in tumors of histologic grade II (p < 0.05). There was good concordance between PR expression in core biopsy and surgical specimens (κ = 0.695). Conclusion: PR was positive in 66.0% of breast carcinoma cases, including 7.8% with low expression (1–10%). PR assessment showed good agreement between core needle biopsy and surgical specimens, supporting the reliability of biopsy evaluation in routine diagnostic practice.
Article Details
Keywords
Breast cancer, progesterone receptor, PR
References
2. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346-1366.
3. Slostad JA, Yun NK, Schad AE, et al. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience. Cancer Med. 2022;11(24):4954-4965.
4. SEER Cancer Statistics Review. Cancer Stat Facts: Female Breast Cancer. National Cancer Institute. 2023.
5. Cheng SA, Liang LZ, Liang QL, et al. Breast cancer laterality and molecular subtype likely share a common risk factor. Cancer Manag Res. 2018;10:6549-6554.
6. Mai Chí Thành, Trần Thị Kim Phượng, Vũ Thị Hồng và cộng sự. Đặc điểm lâm sàng và mô bệnh học ở bệnh nhân ung thư vú trẻ tuổi tại Bệnh viện Trung ương Thái Nguyên. Tạp chí Y học Việt Nam. 2024;3:80-86.
7. Shawn Michael Doss, Priyanka Raval. The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy. J Clin Oncol. 2025;43:521.
8. AlZaman AS, Mughal SA, AlZaman YS, et al. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J. 2016;37(1):37-42.
9. Senel, Fatma. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features. Indian Journal of Pathology and Microbiology. 2021;64(4):671-676.
10. Rossi C, Fraticelli S, Fanizza M, et al. Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature. Breast Cancer Res Treat. 2023;198(3):573-582.